The global heart valve devices market was valued at US$10.9 billion in 2023 and is projected to expand at a CAGR of 11.7% from 2024 to 2034, reaching more than US$38.2 billion by the end of 2034. Rising cardiovascular disease prevalence, an aging global population, increased healthcare investments, and advances in minimally invasive procedures are expected to remain key factors supporting market growth.

Heart valve devices play an important role in treating damaged or diseased valves caused by aging, calcification, congenital conditions, and rheumatic heart disease. These devices help restore normal blood flow and prevent backward leakage during the cardiac cycle. Major product categories include biological surgical valves, mechanical valves, and transcatheter heart valves.

Rising Cardiovascular Disease Burden Drives Demand

The growing prevalence of cardiovascular disorders is a major catalyst for the heart valve devices market. Increasing life expectancy and the expanding geriatric population are contributing to a higher incidence of age-related valvular diseases, particularly aortic stenosis.

Growing rates of hypertension and obesity are also expected to increase the burden of cardiovascular conditions in the coming years. As healthcare systems focus on early diagnosis and effective treatment, demand for advanced heart valve repair and replacement technologies is likely to rise.

TAVI Adoption Strengthens Market Prospects

Transcatheter aortic valve implantation (TAVI) has emerged as a major growth area in the heart valve devices industry. The minimally invasive nature of TAVI, combined with shorter recovery times and improvements in procedural safety and efficacy, has encouraged its adoption among eligible patients.

The expansion of TAVI indications, including treatment of selected lower-risk patients, has further broadened the addressable patient population. Continued technological advances are expected to improve device durability, implantation accuracy, and patient outcomes.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=486

Aortic Valves and Biological Valves Lead

Among valve types, aortic valves account for a significant share of the market, primarily due to the increasing prevalence of aortic stenosis. The availability of both surgical and transcatheter treatment options is creating additional opportunities in this segment.

Based on material, biological valves are gaining strong traction. Tissue valves manufactured using bovine or porcine tissue offer functional characteristics that closely resemble natural heart valves. Improvements in tissue treatment and anti-calcification technologies are also helping enhance their durability and clinical performance.

North America Remains a Leading Market

North America held a dominant share of the global heart valve devices market in 2023, supported by advanced healthcare infrastructure, substantial research investments, and high healthcare expenditure. The region also benefits from the presence of leading medical device manufacturers and rapid adoption of innovative technologies.

Europe is expected to remain an important market, while Asia Pacific is projected to register the highest growth rate during the forecast period. Rising healthcare expenditure, an expanding elderly population, increasing commercialization of medical devices, and growing adoption of transcatheter procedures are creating significant opportunities across the region.

Competitive Landscape

The market features several established and emerging companies focused on developing innovative valve repair and replacement technologies. Key players include Medtronic plc, Boston Scientific Corporation, Abbott, Edwards Lifesciences Corporation, Foldax Inc., Novostia SA, Meril Life Sciences Pvt. Ltd., Corcym UK Limited, JenaValve Technology, Inc., and MicroPort Scientific Corporation.

Recent product launches and regulatory approvals highlight the industry's focus on improving valve durability, ease of implantation, procedural efficiency, and minimally invasive treatment options.

Overall, the heart valve devices market is positioned for strong expansion through 2034. Continued innovation, rising cardiovascular disease prevalence, improved access to advanced healthcare, and increasing preference for minimally invasive interventions are expected to create substantial opportunities for market participants.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453